RepliCel Life Sciences Balans Gezondheid
Financiële gezondheid criteriumcontroles 0/6
RepliCel Life Sciences has a total shareholder equity of CA$-5.0M and total debt of CA$1.2M, which brings its debt-to-equity ratio to -25%. Its total assets and total liabilities are CA$172.7K and CA$5.2M respectively.
Belangrijke informatie
-25.0%
Verhouding schuld/eigen vermogen
CA$1.24m
Schuld
| Rente dekkingsratio | n/a |
| Contant | CA$148.95k |
| Aandelen | -CA$4.98m |
| Totaal verplichtingen | CA$5.15m |
| Totaal activa | CA$172.68k |
Recente financiële gezondheidsupdates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: REPC.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: REPC.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: REPC.F has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: REPC.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Schuldendekking: REPC.F's operating cash flow is negative, therefore debt is not well covered.
Rentedekking: Insufficient data to determine if REPC.F's interest payments on its debt are well covered by EBIT.